As the receptor for HGF, c-MET, has been shown to be upregulated in androgen-insensitive and metastatic prostate cancer cells (Humphrey et al., 1995), it would be interesting in future work to test whether this is linked to increased invasiveness via EphA receptor-mediated CIL. The gene discussed is MET; the disease is prostate carcinoma.